Simranjit is an Operating Partner at Keensight.
Simranjit has more than 18 years of senior management experience in Asia Pacific working with biopharma, diagnostics and medical device companies for their R&D, business expansion, and growth strategies for the region.
Simran is currently the CEO of Guardant Health AMEA (GH AMEA), a precision oncology company which is a pioneer in comprehensive genomic profiling (liquid biopsies). The company has a vast portfolio of diagnostic tests across the continuum of cancer from late-stage cancer to recurrence monitoring to early cancer detection. It has a presence across 41 countries in Asia, Middle East & Africa. Simran also sits on the oversight committee of the National Health Innovation Centre under the auspices of MOH Singapore & the Evaluation committee for the Diagnostics Development Hub under the Agency for Science, Technology & Research
Prior to Guardant Health, Simran was the Vice President of the Global medical devices & diagnostics division & Head of Strategic Planning Asia for IQVIA, a Global CRO where he was instrumental to drive IQVIA’s growth strategy for Asia Pacific and accelerate revenue growth.